Leading stakeholders in the industry react to how evolving US policies, payer demands, and vertical integration are reshaping ...

Immuno Cure BioTech and PharmaJet are working together on a clinical study to test the effectiveness of PharmaJet’s ...

According to Sun Life, cancer is the most common and costly condition that its members face. Second opinions are important and can often play an important role in the decisions patients make in their ...

Cancer patients’ journeys are complex and the benefit of a drug goes well beyond survival, even in cases of incurable and/or ...

With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

Approval was based on results from the Phase III inMIND trial, which demonstrated a statistically significant and clinically ...

The decision to advance prasinezumab to Phase III was based on results from the Phase IIb PADOVA trial, which demonstrated ...

FDA approves first targeted therapy for bullous pemphigoid (BP): Dupixent (dupilumab) becomes the first and only targeted ...

The key to improving SFE in 2025 lies in fundamentally reorienting measurement from representative activities to the value ...

Mike Hollan is an assistant managing editor for Pharmaceutical Executive and Medical Device and Technology and can be reached at mhollan@mjhlifesciences.com.

The traditional approach to trial management relies on a mix of solutions that often become siloed and difficult to integrate ...

The companies are working together to make it easier for companies to offer health plans that include these medications.